HMBD-001

Clinical Trials Overview

2 trials found
About HMBD-001

HMBD-001 is an experimental drug currently being studied in clinical trials for certain advanced solid tumors, including those with high levels of the HER3 protein or specific gene changes (like NRG1 fusions). It is a monoclonal antibody, meaning it's designed to target a specific protein involved in cancer growth. The trials are designed to determine the safest dose of HMBD-001, understand its side effects, and see if it can shrink tumors or slow their growth, both when given alone and in combination with other cancer drugs like enzalutamide. While not yet approved for colorectal cancer, the trials are investigating its potential in cancers expressing HER3 or having NRG1 fusions, which might include some colorectal cancers. The trials are in early phases, focusing on safety and initial effectiveness.

Category Other Medications
Mechanism HMBD-001 is a monoclonal antibody designed to target the HER3 protein. HER3 is found on the surface of some cancer cells and plays a role in their growth and survival. By binding to HER3, HMBD-001 aims to interfere with the signals that promote cancer cell growth, potentially leading to their death or slowing their proliferation. The specific mechanism by which HMBD-001 affects HER3 signaling is being further investigated in clinical trials.
2
Total Trials
0
Recruiting
2
Active
0
Completed
149
Total Enrollment
2
Countries
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
NCT05919537 Phase 1 Active 68 patients
Start: Sep 2023
End: Mar 2031
INTERVENTIONAL
Medications: Docetaxel Gemcitabine HMBD-001 Nab-Paclitaxel
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
Australia
View Details ClinicalTrials.gov Am I eligible?
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
NCT05057013 Phase 1 Active 81 patients
Start: Nov 2021
End: Nov 2025
INTERVENTIONAL
Medications: Enzalutamide HMBD-001
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours. The main aims are to find out the best dose of HMBD-001 that can be given to participants alone and...
United Kingdom
View Details ClinicalTrials.gov Am I eligible?
Back to Drug Glossary View All Trials